Chemolipiodolization with or without embolization in transcatheter arterial chemoembolization combined with radiofrequency ablation for hepatocellular carcinoma—propensity score matching analysis
PDF | HTML | How to cite
Metrics: PDF 1246 views | HTML 1522 views | ?
Feng Shi1,*, Liang Zhang1,*, Shuai Li2,*, Cai-Jin Lin3,*, Lu-Jun Shen1, Chao-Feng Li1, Mei Jie3, Zhi-Wen Li3, Pei-Hong Wu1
1State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
2The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
3Zhong-shan School of Medicine, Sun Yat-Sen University, Guangzhou, China
*These authors have contributed equally to this study
Pei-Hong Wu, email: [email protected]
Keywords: transcatheter arterial chemoembolization, radiofrequency ablation, hepatocellular carcinoma, Milan criteria, propensity score matching analysis
Received: December 20, 2015 Accepted: March 31, 2016 Published: April 21, 2016
To retrospectively compare the outcome of chemolipiodolization with or without embolization in transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in Patients with hepatocellular carcinoma (HCC) within the Milan criteria. From August 2002 to December 2014, 112 patients (median age, 56.7 years; age range, 22–80 years; 97 men, 15 women) underwent TACE with gelatin sponge particle embolization, and 125 patients (median age, 56.6 years; age range, 23–82 years; 109 men, 16 women) underwent TACE without embolization. RFA was performed within 2 weeks after the TACE. Cumulative overall survival (OS) and disease-free survival (DFS) rates were compared before and after propensity score matching. Before matching, the 1-, 3-, and 5-year OS rate were 96%, 80%, and 62% for embolization group and 94%, 76%, and 59% for non-embolization group . The 1-, 3-, and 5-year DFS rate were 77%, 38%, and 30% for embolization group and 75%, 35%, and 26% for non-embolization group. After matching, the 1-, 3-, and 5-year OS rate were 97%, 82%, and 62% for embolization group and 92%, 74%, and 56% for non-embolization group. The 1-, 3-, and 5-year DFS rate were 79%, 36%, and 30% for embolization group and 74%, 33%, and 26% for non-embolization group. There were no significant difference in OS and DFS rates between the two groups before matching (P =0.999 and P =0.654) and after matching (P =0.951 and P =0.670). In conclusion, embolization in TACE combined with RFA could not improve the survival for patients with HCC within the Milan criteria.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.